Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer


Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

“Our principle using the bridging drug is only to stabilize. We do not hope to choose a very effective method to make our patient better... in fact, we cannot do that because in the cell therapy stage we definitely have no very good choice.”

At the European Society for Medical Oncology (ESMO) 2022 Congress, September 9-13, 2022, in Paris, France, Weijia Fang, MD, Department of Medical Oncology, The First Affiliated Hospital of Zhejiang University, presented data from a phase 1 clinical trial (NCT05028933) for IMC001, an investigational chimeric antigen receptor (CAR) T-cell therapy which targets the EpCAM protein. The ongoing clinical trial is treating patients with advanced gastric and colorectal cancers who have no standard treatment options remaining.

In an interview with CGTLive, Fang commented on a limitation of the clinical trial’s design that was pointed out by Alessandra Curioni, MD, Center of Hematology and Oncology, University Hospital Zurich, during an invited discussion of the study presentation at ESMO. The limitation related to the use of a bridging chemotherapy before the administration of IMC001.

Guoqiang Ai, MD, Immunofoco Biotech Co., also joined the interview to expand on future plans for the clinical trial, describing the planned second stage, which will combine IMC001 with radiofrequency or microwave ablation therapy. Fang rounded out the interview by discussing potential future research into methods of determining which patients can benefit most from cell therapies, mentioning liquid biopsy as an area of interest.

For more coverage of ESMO 2022, click here. 

Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
© 2024 MJH Life Sciences

All rights reserved.